clinical trial · NCT03623243
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Multiple SclerosisRelapsing Multiple SclerosisAdvancing Multiple SclerosisSiponimod
brief summary
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
started
Feb 14, 2019
primary completion
Jul 6, 2022
completion
Jul 6, 2022
last updated
Jun 20, 2024
detailed description
This is a 6-month, open-label, multi-center, single arm design, including advancing RMS patients, evaluating the overall safety and tolerability profile of converting from oral, injectable or infusion RMS DMTs to oral siponimod.
official title
Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol